REDATE MELIANE DIANE-35 GEOGYNON GYNORIT AMNORIL NORDETTE-28 PENORIT NOVA NOVA NOVA ED PILLS NOVODOL NOVODOL FAMILA-28 F FAMILA-28 FAMILA-28 DESOFAM ACNOT DUETON GYNERIC QUEEN QUEEN QUEEN-F QUEEN-F EVA35 MENSTROGEN MARVELON ISMILA -28 F ISMILA -28 F FEMESTELLE-35 HYTRADE-N HYTRADE-C

Dose: 0.4 mg
Single Dose: 0.4 (0.4)
Frequency: 24 hourly
Route: PO
Instructions: 5-7 Days per week for 1-3 Years

Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group

Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group

. It is of Synthetic origin and belongs to Oestrogen. It belongs to Oestrogen Agonist pharmacological group on the basis of mechanism of action and also classified in Sex Hormones and Estrogen Derivatives, Acne Therapy pharmacological group.The Molecular Weight of Ethinyloestradiol is 296.40. Its pKa is 10.34.

Ethinyloestradiol is contraindicated in conditions like Thromboembolism,Genital bleeding,Jaundice,Thrombophlebitis,Cerebrovascular disease,Hepatic carcinoma,Coronary artery disease,Estrogen-dependent cancer,Untreated endometriosis.

The severe or irreversible adverse effects of Ethinyloestradiol, which give rise to further complications include Impotence, Loss of libido, Gynacomastia, Chloasma, MI.Ethinyloestradiol produces potentially life-threatening effects which include Pulmonary embolism, Hypertension, Venous thromboembolism, Endometrial carcinoma, Endometrial hyperplasia, Cerebral thrombosis, Gall bladder disease, Liver tumors, Breast carcinoma, Venous thromboembolism, Coronary thrombosis. which are responsible for the discontinuation of Ethinyloestradiol therapy.The signs and symptoms that are produced after the acute overdosage of Ethinyloestradiol include Nausea, Vomiting, Coronary thrombosis, Uterine withdrawal bleeding.The symptomatic adverse reactions produced by Ethinyloestradiol are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Nausea, Vomiting, Weight gain, Fluid retention, Intermenstrual bleeding or spotting, Chloasma, Cholestatic Jaundice, Vaginal candidiasis, dizziness.

Ethinyloestradiol is primarily indicated in conditions like Breast cancer, Breast cancer (unlicensed indication), Dysfunctional uterine bleeding, Gonadal dysgenesis, Heriditary haemorrhagic telangiectasia, Hormone replacement for menopausal symptoms, Hormone replacement therapy, Menopausal symptoms, Oestrogen deficiency, Osteoporosis prophylaxis, Pre-ovulatory mucus, Prostatic cancer, and can also be given in adjunctive therapy as an alternative drug of choice in Acne, Contraception, Endometriosis, Hirsutism, Menstruation disorders.

Ethinyloestradiol is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAlcoholAmpicillinAprepitantUpon coadministration with aprepitant capsules, the efficacy of hormonal contraceptives during and for 28 days following the last dose of aprepitant capsules may be reduced. Alternative or back-up methods of contraception should be used during treatment with aprepitant capsules and for 1 month following the last dose of aprepitant.Ascorbic AcidChloramphenicolClavulanic AcidCo-AmoxiclavCyproterone (Acetate)GriseofulvinImipramine (HCl)LynoestrenolMeprobamatePhenobarbitonePhenylbutazone Phenytoin (Na)RifampicinSt.Johns Wort ExtractConcurent use may result in irregular menstrual flow.TegaserodTegaserod decreased Ethinyloestradiol plasma concentrations by less than 10% in a clinical study with a low-dose triphasic oral contraceptive (n=45). The mechanism is unknown. There were no changes in ethinyl estradiol concentrations or in contraceptive efficacy. No action is necessary.MinorTetracycline (HCl) These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Tests for measuring urinary oestradiol, oestrogens and oestrone Tests for thyroid + glucose tolerance

Drug should not be given to Paediatrics, Pregnant Mothers, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Tab Store in a well closed container. Protect from Sunlight.

High doses of ethinyloestradiol used in treatment of malignant disease should be used with caution in patients with cerebrovascular disorder, coronary artery disease or venous thromboembolism. It should be used with caution in children, because premature closure of epiphysis may occur resulting in inhibited linear growth and small stature.